Please login to the form below

Not currently logged in
Email:
Password:

Zealand Pharma

This page shows the latest Zealand Pharma news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolsters NASH pipeline with $870m Yuhan deal

Boehringer bolsters NASH pipeline with $870m Yuhan deal

therapies. Boehringer is a diabetes specialist and already has a dual GLP-1 and glucagon agonist, partnered with Zealand Pharma, in phase 1b testing. ... later this year, as well as a drug candidates for the disease covered by its recently expanded $201m

Latest news

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Acquisition. $244m. Zealand/. Royalty Pharma. Royalty streams and milestones for Soliqua 100/33/. ... So two opportunities here – acquisition of animal health products and out-licensing to Bayer’s pharma business.

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    For an indepth analysis of these deals, read'Pharma deals during July 2014'. ... 635. Zealand Pharma/ Boehringer Ingelheim. R&D collaboration. Peptide discovery collaboration with cardio-metabolic focus.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • David Horn Solomon takes the helm of Akari Therapeutics David Horn Solomon takes the helm of Akari Therapeutics

    David has a strong track record of leading phase II stage companies like Akari, most notably at Zealand Pharma where he led the development of lixisenatide, which is now commercialised by ... Sanofi.”. His other roles have included CEO at Bionor Pharma

  • Glythera appoints Dr Mike Owen Glythera appoints Dr Mike Owen

    Owen is also currently a director of Avacata plc, Blink Biomedical SAS, GammDelta Therapeutics, Ossianix Inc, ReNeuron plc and Zealand Pharma A/S. ... pipeline and building strategic partnerships with large pharma.”.

  • Bionor names executive management team additions Bionor names executive management team additions

    He has extensive experience as head of operation in public and private research intensive organisations and most recently served as director and general counsel to the management at Zealand Pharma. ... Rolstead has over 15 years of experience and has

  • Zealand announces management changes Zealand announces management changes

    Zealand Pharma is set to make a series of restructuring changes that will shake-up a number of positions at the firm.  . ... The R&D arm of Zealand will be split into two parts, each with direct representation in management, while investor relations and

  • Zealand's Arvind Hundal steps down as chief business officer Zealand's Arvind Hundal steps down as chief business officer

    She leaves after five years with the Danish biotech company. Dr Arvind Hundal has left Danish biotech company Zealand Pharma to pursue other opportunities.  . ... served as a member of AstraZeneca's strategic planning business development organisation

More from appointments
Approximately 5 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics